← back to search

Chris Twelves

University of Leeds · GB
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, and Colorectal Cancer Treatments and Studies.
h-index
27
citations
3,358
works
82
NIH funding
primary concept
Medicine
email

Recent publications

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
Annals of Oncology 2024cited by 58position: middledoi
Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer
Cancer Research 2023cited by 14position: middledoi
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
Journal of Clinical Oncology 2022cited by 41position: middledoi
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
JAMA Oncology 2022cited by 23position: middledoi
Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer
Cancer Research 2021cited by 32position: middledoi
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study
PLoS ONE 2016cited by 9position: middledoi
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Breast Cancer Research and Treatment 2014cited by 214position: firstdoi
Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency
Journal of Hepatology 2014cited by 97position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Richard D. Baird · Cancer Research UK2 papers (2022–2024)Tim Brier · AstraZeneca (United Kingdom)2 papers (2022–2024)Manuel Ruíz Borrego · Universidad de Sevilla2 papers (2022–2024)Peter Kabos · University of Colorado Health2 papers (2022–2024)Manuel Ruíz‐Borrego · Royal College of Surgeons in Ireland2 papers (2022–2024)Anne Armstrong · University of Manchester2 papers (2022–2024)Teresa Klinowska · AstraZeneca (United Kingdom)2 papers (2022–2024)Nicholas C. Turner · Queensland University of Technology2 papers (2022–2024)Christos Vaklavas · University of Utah2 papers (2022–2024)Christopher J. Morrow · AstraZeneca (United Kingdom)2 papers (2022–2024)Justin P.O. Lindemann · AstraZeneca (Netherlands)2 papers (2022–2024)Jason Incorvati · Case Comprehensive Cancer Center2 papers (2022–2024)Eva Ciruelos · Breast Cancer Research Foundation2 papers (2022–2024) · 1 papers (2014–2014) · 1 papers (2014–2014)Leila Dorling · Cancer Research UK Cambridge Center1 papers (2016–2016)Helena Earl · University of Cambridge1 papers (2016–2016) · 1 papers (2014–2014) · 1 papers (2014–2014)Carlos Caldas · Concern Foundation1 papers (2016–2016)